SOFT TISSUE AUGMENTATION: THE INTERNATIONAL PERSPECTIVE
For the last few decades, aesthetic dermatology has become increasingly popular. Most of our patients want to enhance their look without downtime. As aesthetic surgery continues to have a tremendous role in the growth of our specialty, cosmetic dermatology is growing, with many different techniques for “rejuvenation”. Among them, injection techniques with filler agents are a common part of everyday medical practice.
For the last few decades, aesthetic dermatology has become increasingly popular. Most of our patients want to enhance their look without downtime.
The increasing need for long-lasting injectable soft tissue fillers for the treatment of wrinkles and folds requires a critical discussion of the biocompatibility on a scientific background.
Since 1996, hyaluronic acid (HA) has been launched onto the market in Europe. Since then, different companies proposed their HAs. Biomatrix (NJ, USA) proposes an animal-derived HA (from rooster comb). Q–Med AB (Uppsala, Sweden) and LEA-DERM (Paris, France) are the main companies to have a nonanimal HA.
Poly-L-lactic acid (PLA) New-Fill* is one of the latest implants commercialized among bioresorbable fillers. This synthetic polymer is biocompatible, biodegradable, immunologically inert, and free from toxicity.
Artecoll was developed about 20 years ago and underwent a number of production changes until it recently became FDA approved under the new name of Artefill.